Results from the landmark NHS‑Galleri trial in England show that annual multi‑cancer screening with the Galleri test significantly increases early cancer detection and reduces Stage IV diagnoses in deadly cancers, offering new population‑level evidence for shifting the cancer detection paradigm.
The randomised, controlled study was carried out across England's National Health Service (NHS) in more than 142,000 adults aged 50-77.
It compared standard-of-care screening with and without the addition of Galleri, a blood‑based multi‑cancer early detection (MCED) test developed by GRAIL.
Although the trial did not meet its primary endpoint of a statistically significant reduction in combined Stage III and IV diagnoses, a strong, favourable trend was observed during sequential screening rounds.
Crucially, adding the Galleri test to existing NHS screening programmes resulted in a clinically meaningful reduction in Stage IV cancers among 12 deadly cancer types (including lung, pancreas, ovary and colorectal cancers) with more than 20 % fewer late‑stage diagnoses in the second and third annual rounds.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.